362 related articles for article (PubMed ID: 36071839)
21. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
22. Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment.
Kumar AR; Devan AR; Nair B; Nath LR
Curr Drug Targets; 2021; 22(11):1288-1316. PubMed ID: 33538672
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
24. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
25. HSP90α Mediates Sorafenib Resistance in Human Hepatocellular Carcinoma by Necroptosis Inhibition under Hypoxia.
Liao Y; Yang Y; Pan D; Ding Y; Zhang H; Ye Y; Li J; Zhao L
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33440739
[TBL] [Abstract][Full Text] [Related]
26. Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.
Shrestha R; Prithviraj P; Bridle KR; Crawford DHG; Jayachandran A
J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925488
[TBL] [Abstract][Full Text] [Related]
27. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
28. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B
Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430
[TBL] [Abstract][Full Text] [Related]
30. Targeting hypoxia-inducible factor-2α enhances sorafenib antitumor activity via β-catenin/C-Myc-dependent pathways in hepatocellular carcinoma.
Liu F; Dong X; Lv H; Xiu P; Li T; Wang F; Xu Z; Li J
Oncol Lett; 2015 Aug; 10(2):778-784. PubMed ID: 26622569
[TBL] [Abstract][Full Text] [Related]
31. Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma
Liu ZY; Zhang DY; Lin XH; Sun JL; Abuduwaili W; Zhang GC; Xu RC; Wang F; Yu XN; Shi X; Deng B; Dong L; Weng SQ; Zhu JM; Shen XZ; Liu TT
Front Pharmacol; 2022; 13():952482. PubMed ID: 36071851
[TBL] [Abstract][Full Text] [Related]
32. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V
Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667
[TBL] [Abstract][Full Text] [Related]
33. The Complexity of the Tumor Microenvironment in Hepatocellular Carcinoma and Emerging Therapeutic Developments.
Argentiero A; Delvecchio A; Fasano R; Andriano A; Caradonna IC; Memeo R; Desantis V
J Clin Med; 2023 Dec; 12(23):. PubMed ID: 38068521
[TBL] [Abstract][Full Text] [Related]
34. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.
Wang S; Wang Y; Xun X; Zhang C; Xiang X; Cheng Q; Hu S; Li Z; Zhu J
J Exp Clin Cancer Res; 2020 Jan; 39(1):22. PubMed ID: 31992334
[TBL] [Abstract][Full Text] [Related]
35. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
36. Targeting tumor-infiltrating Ly6G
Chang CJ; Yang YH; Chiu CJ; Lu LC; Liao CC; Liang CW; Hsu CH; Cheng AL
Int J Cancer; 2018 May; 142(9):1878-1889. PubMed ID: 29266245
[TBL] [Abstract][Full Text] [Related]
37. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
38. Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
Li D; Sun FF; Wang D; Wang T; Peng JJ; Feng JQ; Li H; Wang C; Zhou DJ; Luo H; Fu ZQ; Zhang T
Oncol Res; 2020 Dec; 28(5):467-481. PubMed ID: 32560747
[TBL] [Abstract][Full Text] [Related]
39. Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p.
Ye J; Zhang R; Du X; Chai W; Zhou Q
Onco Targets Ther; 2019; 12():415-422. PubMed ID: 30655679
[TBL] [Abstract][Full Text] [Related]
40. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
Lai YL; Wang KH; Hsieh HP; Yen WC
J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
